author-photo

Ying Chen

Pfizer

36

Papers

695

Citations

Citation Trend

Filter By

Papers (24) Sort By

Journal Conference Others

CLO21-017: Hospitalization and Supportive Care Measure (SCM) Utilization in Patients With Germline BRCA1/2 Mutated (gBRCA1/2mut) HER2- Advanced Breast Cancer (ABC) in EMBRACA: Results From an Extended Follow-up Post-hoc Analysis

2021 Journal of The National Comprehensive Cancer Network
Show All
- Source
- Cite
- Save
Citations (0)
Exploring impact of mutations in non-BRCA DNA damage response (DDR) and non-DDR genes on efficacy in phase III EMBRACA study of talazoparib (TALA) in patients (pts) with germline BRCA1/2 mutated (gBRCAm) HER2-negative (HER2-) advanced breast cancer (ABC).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (14)
A Phase I study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study).

2020 Blood
Show All
- Source
- Cite
- Save
Citations (11)
A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 Study

2019 Blood
Show All
- Source
- Cite
- Save
Citations (12)
A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors

2019 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (14)
Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer

2018 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (94)
Assessment of clinical immunogenicity of inotuzumab ozogamicin in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia

2018 AAPS Open
Show All
- Source
- Cite
- Save
Citations (4)
Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (36)
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

2017 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (107)